Difference between revisions of "Afuresertib (GSK-2110183)"
Jump to navigation
Jump to search
m (Jwarner moved page Afuresertib to Afuresertib (GSK2110183)) |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 4: | Line 4: | ||
==Preliminary results== | ==Preliminary results== | ||
===[[Multiple myeloma]]=== | ===[[Multiple myeloma]]=== | ||
| − | # Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. [http://www.bloodjournal.org/content/124/14/2190 link to original article] [ | + | # Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. [http://www.bloodjournal.org/content/124/14/2190 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25075128 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 02:52, 2 December 2016
Mechanism of action
Oral AKT1 inhibitor
Preliminary results
Multiple myeloma
- Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. link to original article PubMed